Celldex Therapeutics, Inc. (NASDAQ:CLDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On August 7, 2019, Celldex Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter of 2019. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release of Celldex Therapeutics, Inc., dated August 7, 2019.
Celldex Therapeutics, Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Celldex Provides Corporate Update and Reports Second Quarter 2019 Results HAMPTON,…
To view the full exhibit click here
About Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
